Influence of myopic macular degeneration severity on treatment outcomes with intravitreal aflibercept in the MYRROR study.

Journal Article (Clinical Trial, Phase III;Journal Article;Multicenter Study)

PURPOSE: To determine the influence of baseline myopic macular degeneration (MMD) severity on outcomes with intravitreal aflibercept (IVT-AFL) in patients with myopic choroidal neovascularization (CNV). METHODS: MYRROR was a randomized, double-masked study in patients with myopic CNV treated with IVT-AFL/sham over 48 weeks. At baseline/week 48, images were retrospectively graded for MMD. RESULTS: At baseline, 115 eyes had a valid MMD grading result; at week 48, grading results were available for 99 eyes [IVT-AFL (n = 78)/sham (n = 21)]. Severity of baseline MMD was distributed as follows: category 1: 19/115 (17%); category 2: 67/115 (58%); category 3: 22/115 (19%); category 4: 7/115 (6%). Higher MMD category was associated with older age (nominal p = 0.007) and longer axial length (nominal p = 0.025). At week 48, patients in the mild and severe groups had visual acuity gains of +13.5 and +12.4 letters, respectively. Baseline MMD severity did not significantly affect visual/anatomical outcomes or number of treatments. Visual Functioning Questionnaire-25 scores improved more in mild (+5.6) versus severe (+0.4) MMD (nominal p = 0.03). There were no new safety events. CONCLUSIONS: Visual acuity gains, morphological outcomes and dosing frequency were not affected by baseline MMD severity in patients treated with IVT-AFL. A benefit with IVT-AFL treatment was observed for all baseline MMD stages included in this study.

Full Text

Duke Authors

Cited Authors

  • Cheung, CMG; Ohno-Matsui, K; Wong, TY; Li, T; Asmus, F; Leal, S; MYRROR Study Investigators,

Published Date

  • August 2019

Published In

Volume / Issue

  • 97 / 5

Start / End Page

  • e729 - e735

PubMed ID

  • 30690902

Electronic International Standard Serial Number (EISSN)

  • 1755-3768

Digital Object Identifier (DOI)

  • 10.1111/aos.14035


  • eng

Conference Location

  • England